中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | phenyl-1-(N-benzyloxycarbonylamino)-2-(phenyl)ethylphosphonate | —— | C22H22NO5P | 411.394 |
—— | diphenyl α-N-(propiolamido)-2-phenylethylphosphonate | 1450636-18-6 | C23H20NO4P | 405.39 |
—— | diphenyl (1-amino-2-phenyl)ethylphosphonate | 73270-44-7 | C20H20NO3P | 353.357 |
—— | methyl <1- |
107072-64-0 | C17H20NO5P | 349.323 |
—— | dimethyl 1-benzyloxycarbonylamino-2-phenylethyl phosphonate | 84690-42-6 | C18H22NO5P | 363.35 |
—— | diethyl-1-[(benzyloxycarbonyl)amino]-2-phenylethyl phosphonate | 107072-80-0 | C20H26NO5P | 391.404 |
Enzyme specific inhibitors can be designed based on endogenous substrate peptide motifs and modified to yield specific activity-based probes (ABPs). The development/validation of a theranostic ABP-inhibitor prototype for KLK7 protease is presented.